Elite Pharmaceuticals Inc (ELTP)

[Couch]

“We are pleased to have reached agreement with the FDA on the Special Protocol Assessment for our Phase 3 clinical trial for ELI-216, our abuse deterrent oxycodone formulation. The SPA agreement is a significant milestone for Elite and provides a clearly defined pathway towards regulatory approval of the company’s New Drug Application.”